"id","versionIdentifier","instanceType","rationale","uuid:ID"
"StudyVersion_1","2","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","f1f1a7ad-0594-4ed5-aa8e-3485d0422bf0"
